StreetInsider.com News Articles

Form 4 Q32 Bio Inc. For: Aug 25 Filed by: Morrison Jodie Pope

Thu, 27 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260827/26989972.html

Form 4 Q32 Bio Inc. For: Aug 25 Filed by: Morrison Jodie Pope

Thu, 27 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260827/26989972.html

Form 4 Q32 Bio Inc. For: Aug 25 Filed by: Kalowski Lee

Thu, 27 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260827/26989975.html

Form 4 Q32 Bio Inc. For: Aug 25 Filed by: Kalowski Lee

Thu, 27 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260827/26989975.html

Form 4 Q32 Bio Inc. For: Aug 25 Filed by: Violette Shelia M.

Thu, 27 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260827/26989978.html

Form 4 Q32 Bio Inc. For: Aug 25 Filed by: Violette Shelia M.

Thu, 27 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260827/26989978.html

Morgan Stanley Starts Q32 Bio Inc. (QTTB) at Overweight

Mon, 24 Aug 2026 04:47:15 -0400

Morgan Stanley analyst Judah Frommer initiates coverage on Q32 Bio Inc. (NASDAQ: QTTB) with a Overweight rating and a price target of $34.00.

The analyst comments: “We initiate coverage of Q32 Bio (QTTB) with an Overweight rating and a $34 price target. Q32 is a clinical-stage immunology company developing bempikibart, a fully human, effectorless monoclonal antibody targeting IL-7Rα, for severe or very severe alopecia areata. Three oral JAK inhibitors are currently approved for severe AA and have established that systemic treatment can produce meaningful hair regrowth. Broader uptake, however, remains constrained by class boxed warnings, laboratory-monitoring requirements and the need for

Morgan Stanley Starts Q32 Bio Inc. (QTTB) at Overweight

Mon, 24 Aug 2026 04:47:15 -0400

Morgan Stanley analyst Judah Frommer initiates coverage on Q32 Bio Inc. (NASDAQ: QTTB) with a Overweight rating and a price target of $34.00.

Form SCHEDULE 13G/A Q32 Bio Inc. Filed by: Point72 Asset Management, L.P.

Fri, 14 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260814/26930612.html

Form SCHEDULE 13G/A Q32 Bio Inc. Filed by: Point72 Asset Management, L.P.

Fri, 14 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260814/26930612.html

Form SCHEDULE 13G/A Q32 Bio Inc. Filed by: Sirenia Capital Management LP

Fri, 14 Aug 2026 08:35:00 -0400

si-local-file:///var/storage/secattach/20260814/26925238.html

Form SCHEDULE 13G/A Q32 Bio Inc. Filed by: Sirenia Capital Management LP

Fri, 14 Aug 2026 08:35:00 -0400

si-local-file:///var/storage/secattach/20260814/26925238.html

Q32 Bio Inc. (QTTB) PT Lowered to $59 at Wells Fargo

Thu, 06 Aug 2026 06:38:18 -0400

Wells Fargo analyst Derek Archila lowered the price target on Q32 Bio Inc. (NASDAQ: QTTB) to $59.00 (from $66.00) while maintaining a Overweight rating.

Q32 Bio (QTTB) Tops Q2 EPS by 13c

Wed, 05 Aug 2026 07:21:18 -0400

Q32 Bio (NASDAQ: QTTB) reported Q2 EPS of ($0.44), $0.13 better than the analyst estimate of ($0.57).

For earnings history and earnings-related data on Q32 Bio (QTTB) click here.

Form 10-Q Q32 Bio Inc. For: Jun 30

Wed, 05 Aug 2026 07:10:00 -0400

si-local-file:///var/storage/secattach/20260805/26870178.html

Form 10-Q Q32 Bio Inc. For: Jun 30

Wed, 05 Aug 2026 07:10:00 -0400

si-local-file:///var/storage/secattach/20260805/26870178.html

Form 8-K Q32 Bio Inc. For: Aug 05

Wed, 05 Aug 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260805/26870096.html

Form 8-K Q32 Bio Inc. For: Aug 05

Wed, 05 Aug 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260805/26870096.html

Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Wed, 05 Aug 2026 06:59:00 -0400

-- Reported positive bempikibart 36-week topline results from Part B of SIGNAL-AA clinical trial; additional details from 36-week results and initial findings from 52-week results to be presented at a medical conference in the second half of 2026 --

-- Patient enrollment and dosing in SIGNAL-AA Part B open-label extension (OLE) ongoing --

-- Registration-directed program evaluating bempikibart in patients with severe or very severe AA expected to initiate in 1H'2027 subject to planned regulatory discussions later this year --

-- Half-life extended fully human anti-IL-7Rα antibody, ADX-914-XL, advancing in pre-clinical development --

-- Completed $200 million public

Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Wed, 05 Aug 2026 06:59:00 -0400

-- Reported positive bempikibart 36-week topline results from Part B of SIGNAL-AA clinical trial; additional details from 36-week results and initial findings from 52-week results to be presented at a medical conference in the second half of 2026 --
-- Patient enrollment and dosing in SIGNAL-AA Part B open-label extension (OLE) ongoing --
-- Registration-directed program evaluating bempikibart in patients with severe or very severe AA expected to initiate in 1H'2027 subject to planned regulatory discussions later this year --
-- Half-life extended fully human anti-IL-7Rα antibody, ADX-914-XL, advancing in pre-clinical development --
-- Completed $200 million public

Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Wed, 05 Aug 2026 06:59:00 -0400

-- Reported positive bempikibart 36-week topline results from Part B of SIGNAL-AA clinical trial; additional details from 36-week results and initial findings from 52-week results to be presented at a medical conference in the second half of 2026 --
-- Patient enrollment and dosing in SIGNAL-AA Part B open-label extension (OLE) ongoing --
-- Registration-directed program evaluating bempikibart in patients with severe or very severe AA expected to initiate in 1H'2027 subject to planned regulatory discussions later this year --
-- Half-life extended fully human anti-IL-7Rα antibody, ADX-914-XL, advancing in pre-clinical development --
-- Completed $200 million public

Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Wed, 05 Aug 2026 06:59:00 -0400

-- Reported positive bempikibart 36-week topline results from Part B of SIGNAL-AA clinical trial; additional details from 36-week results and initial findings from 52-week results to be presented at a medical conference in the second half of 2026 --
-- Patient enrollment and dosing in SIGNAL-AA Part B open-label extension (OLE) ongoing --
-- Registration-directed program evaluating bempikibart in patients with severe or very severe AA expected to initiate in 1H'2027 subject to planned regulatory discussions later this year --
-- Half-life extended fully human anti-IL-7Rα antibody, ADX-914-XL, advancing in pre-clinical development --
-- Completed $200 million public

Form SCHEDULE 13G/A Q32 Bio Inc. Filed by: Opaleye Management Inc.

Fri, 31 Jul 2026 16:06:00 -0400
si-local-file:///var/storage/secattach/20260731/26850627.html

Form SCHEDULE 13G/A Q32 Bio Inc. Filed by: Opaleye Management Inc.

Fri, 31 Jul 2026 16:06:00 -0400
si-local-file:///var/storage/secattach/20260731/26850627.html

Form EFFECT Q32 Bio Inc.

Wed, 29 Jul 2026 06:06:00 -0400
si-local-file:///var/storage/secattach/20260729/26829775.html